Related Experiment Video

Updated: Jan 9, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K

Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic

Ren-Hua Ye1,2, Hong-Jie Jhou3, Hsin-Yu Chen4

  • 1Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.

JCO Oncology Practice
|December 9, 2025
PubMed
Abstract

Insights

First-line osimertinib significantly improves overall survival for patients with metastatic EGFR-mutant non-small cell lung cancer compared to older tyrosine kinase inhibitors. This real-world study also found a more favorable safety profile for osimertinib.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Research

Background:

  • Standard epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used for metastatic EGFR-mutant non-small cell lung cancer (NSCLC).
  • Clinical trials support osimertinib's efficacy, but large real-world comparisons against first-generation TKIs are limited.

Purpose of the Study:

  • To compare the real-world effectiveness and safety of first-line osimertinib versus first-generation TKIs (erlotinib, gefitinib).
  • To emulate a target trial using real-world data for robust comparative analysis.

Main Methods:

  • Retrospective cohort study using the TriNetX Research Network global database.
  • Identified adult patients with newly diagnosed metastatic EGFR-mutant NSCLC initiating first-line EGFR-TKI therapy.
  • Utilized 1:1 propensity score matching (PSM) to compare overall survival (OS) and safety outcomes.

Main Results:

  • Osimertinib demonstrated significantly longer median OS (1,505 days) versus first-generation TKIs (901 days) post-PSM (HR, 0.612; P < .001).
  • Survival benefits were consistent across subgroups, with pronounced effects in Asian patients (HR, 0.439).
  • First-generation TKIs showed higher rates of dermatologic toxicities, severe infections, and hospitalizations; osimertinib had higher rates of abnormal ECG findings and thrombocytopenia.

Conclusions:

  • First-line osimertinib is associated with substantially prolonged OS in metastatic EGFR-mutant NSCLC based on real-world data.
  • Osimertinib offers a favorable safety profile, including reduced severe infections and hospitalizations, compared to first-generation EGFR-TKIs.
  • Target trial emulation provides robust evidence for real-world comparative effectiveness.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
611